Jorge M. Chaves
Expertise in
58
conditions

Dr. Jorge M. Chaves

Oncology
1624 South I Street, Suite 105, 
Tacoma, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
58
conditions
1624 South I Street, Suite 105, 
Tacoma, WA 

Overview

Jorge Chaves is an Oncologist practicing medicine in Tacoma, Washington.

Dr. Chaves is highly rated in 58 conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Large-Cell Immunoblastic Lymphoma.

Dr. Chaves is board certified in Internal Medicine and Medical Oncology. He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 14 clinical trials. Dr. Chaves is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in WA

Board Certifications

Internal Medicine
Medical Oncology

Fellowships

Yale University School of Medicine, New Haven, CT

Hospital Affiliations

Tacoma General Allenmore Hospital
St Michael Medical Center
St Joseph Medical Center
St Anthony Hospital
St Clare Hospital

Languages Spoken

English
Castilian
Filipino
Konkani
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Lifewise

Accepted plan types not found. Please verify directly with the provider.

Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Northwest Medical Specialties - Tacoma
1624 South I Street, Suite 105, Tacoma, WA 98405

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Enrollment Status: Recruiting
Publish Date: November 01, 2023
Intervention Type: Drug
Study Drugs: Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
Study Phase: Phase 1
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
Enrollment Status: Completed
Publish Date: July 01, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
Enrollment Status: Terminated
Publish Date: February 18, 2026
Intervention Type: Drug
Study Drug: HMPL-523
Study Phase: Phase 1
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 1
Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers
Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers
Enrollment Status: Completed
Publish Date: November 27, 2024
Intervention Type: Drug
Study Drugs: ZW25, Paclitaxel, Capecitabine, Vinorelbine
Study Phase: Phase 1
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Drug
Study Drugs: LAE001, Prednisone, Afuresertib
Study Phase: Phase 1/Phase 2
A Phase I, Open-Label Study of GSK1795091 Administered in Combination With Immunotherapies in Participants With Advanced Solid Tumors
A Phase I, Open-Label Study of GSK1795091 Administered in Combination With Immunotherapies in Participants With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 23, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176
Enrollment Status: Completed
Publish Date: August 22, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: March 17, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors
A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: June 16, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

1 Total Publications

A need to monitor P. falciparum resistance to artesunate in Peru
A need to monitor P. falciparum resistance to artesunate in Peru
Journal: Revista peruana de medicina experimental y salud publica
Published: January 23, 2013
Similar Doctors
Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (26.9 miles away)
206-288-1000
Languages Spoken:
English, Castilian, Hindi, Punjabi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Ajay Gopal is an Oncologist practicing medicine in Seattle, Washington. Dr. Gopal is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Follicular Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and Classical Hodgkin Lymphoma. Dr. Gopal is currently accepting new patients.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Swedish Cardiovascular RSRCH

1221 Madison St Ste 1020, 
Seattle, WA 
 (25.2 miles away)
206-215-2658
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Pagel is an Oncologist practicing medicine in Seattle, Washington. Dr. Pagel is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Leukemia, and Bone Marrow Aspiration. Dr. Pagel is currently accepting new patients.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (26.9 miles away)
206-520-5000
Languages Spoken:
English, German, Greek, Italian, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Petros Grivas is an Oncologist practicing medicine in Seattle, Washington. Dr. Grivas is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Endoscopy. Dr. Grivas is currently accepting new patients.

Frequently Asked Questions about Dr. Jorge M. Chaves

How do I make an appointment with Dr. Jorge M. Chaves?

You can book an appointment with Dr. Jorge M. Chaves by calling their office at 253-428-8700. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jorge M. Chaves a top-rated expert for Familial Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jorge M. Chaves is classified as an Distinguished expert for Familial Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jorge M. Chaves specialize in?

While Dr. Jorge M. Chaves is a Oncology, they have specific expertise in Familial Colorectal Cancer, Colorectal Cancer, and Lynch Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jorge M. Chaves participate in research or clinical trials?

Yes. Dr. Jorge M. Chaves has published 1 articles and abstracts on conditions like Familial Colorectal Cancer. You can view a list of Dr. Jorge M. Chaves's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jorge M. Chaves accept my insurance?

Dr. Jorge M. Chaves accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 253-428-8700 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chaves's expertise for a condition
ConditionClose
    View All 17 Distinguished Conditions
    View All 41 Advanced Conditions
    View All 93 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile